Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
JAMA oncology 2025 Apr 03
Management of EGFR-Variant and ALK-Positive Non-Small Cell Lung Cancer Brain Metastasis.
Related Questions
Is it acceptable to treat patients with limited, asymptomatic brain metastases and EGFR-mutant NSCLC with upfront TKI?
Can SRS or whole brain radiotherapy be reserved for progression in these young, healthy patients?
750
×
To continue please login or register
Register
or
Sign in